Science
New Zealand decision follows Australian approval in 2023 of psychedelics to treat PTSD and treatment-resistant depression
This story summarizes reporting from The Guardian. Read the original for full context. Wire items stay in our news sitemap for seven days. Editorial policy.
Read full story on The Guardian →
Global — Agence France-Presse
New Zealand decision follows Australian approval in 2023 of psychedelics to treat PTSD and treatment-resistant depression
Two psychiatrists in New Zealand won approval on Friday to prescribe pharmaceutical-grade MDMA to people with severe post-traumatic stress disorder (PTSD).
The move by New Zealand’s pharmaceutical regulatory body Medsafe makes the country only the second worldwide to approve the party drug for use in treating PTSD, following Australia in 2023.
Two psychiatrists in New Zealand won approval on Friday to prescribe pharmaceutical-grade MDMA to people with severe post-traumatic stress disorder (PTSD).
This report is published with credit to The Guardian. The wire sent a summary; open the original for any extra context. Read on The Guardian →
Source: The Guardian · Agence France-Presse. Published 4 Sept 2026, 04:27 am.
Most relevant
This week’s best wildlife photographs from around the world
Read on The Guardian →
